Meeting
2022 ASCO Annual Meeting
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
Authors
Dirk Schadendorf
University Hospital Essen, Essen and German Cancer Consortium, Heidelberg, Germany
Dirk Schadendorf , Axel Hauschild , Mario Mandalà , John M. Kirkwood , Caroline Robert , Jean-Jacques Grob , Paul D. Nathan , Michael A. Davies , Hiya Banerjee , Rohan Shah , Mike R. Lau , Reinhard Dummer , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT01682083
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9563)
DOI
10.1200/JCO.2022.40.16_suppl.9563
Abstract #
9563
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.
First Author: Reinhard Dummer
Poster
2021 ASCO Annual Meeting
A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.
First Author: Xuan Wang
Poster
2020 ASCO Virtual Scientific Program
Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.
First Author: Lucy Storey
Poster
2019 ASCO Annual Meeting
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).
First Author: Dirk Schadendorf